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Abstract
Aberrant mitochondrial function appears to play a central role in dopaminergic neuronal loss in Parkinson’s disease (PD). 1-
methyl-4-phenylpyridinium iodide (MPP
+), the active metabolite of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), is
a selective inhibitor of mitochondrial complex I and is widely used in rodent and cell models to elicit neurochemical
alterations associated with PD. Recent findings suggest that Glycogen Synthase Kinase-3b (GSK-3b), a critical activator of
neuronal apoptosis, is involved in the dopaminergic cell death. In this study, the role of GSK-3b in modulating MPP
+-
induced mitochondrial dysfunction and neuronal death was examined in vivo, and in two neuronal cell models namely
primary cultured and immortalized neurons. In both cell models, MPTP/MPP
+ treatment caused cell death associated with
time- and concentration-dependent activation of GSK-3b, evidenced by the increased level of the active form of the kinase,
i.e. GSK-3b phosphorylated at tyrosine 216 residue. Using immunocytochemistry and subcellular fractionation techniques,
we showed that GSK-3b partially localized within mitochondria in both neuronal cell models. Moreover, MPP
+ treatment
induced a significant decrease of the specific phospho-Tyr216-GSK-3b labeling in mitochondria concomitantly with an
increase into the cytosol. Using two distinct fluorescent probes, we showed that MPP
+ induced cell death through the
depolarization of mitochondrial membrane potential. Inhibition of GSK-3b activity using well-characterized inhibitors, LiCl
and kenpaullone, and RNA interference, prevented MPP
+-induced cell death by blocking mitochondrial membrane potential
changes and subsequent caspase-9 and -3 activation. These results indicate that GSK-3b is a critical mediator of MPTP/MPP
+-
induced neurotoxicity through its ability to regulate mitochondrial functions. Inhibition of GSK-3b activity might provide
protection against mitochondrial stress-induced cell death.
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Introduction
Parkinson’s disease (PD) is the second most common neurolog-
ical disorder characterized by motor and behavioral disturbances
caused by the degeneration of dopaminergic neurons in the
substantia nigra pars compacta (SNc) [1]. The molecular events
underlying the loss of dopaminergic neurons in PD remain
unclear, although substantial evidence suggest that mitochondrial
dysfunction might be a major contributor [2,3].
Two of the most important functions of mitochondria relate to
the production of ATP by oxidative phosphorylation and the
mediation of signals for apoptotic cell death, the latter being
particularly important in the context of PD. A defect in
mitochondrial complex I activity in PD was identified in substantia
nigra [2] as well as in platelet mitochondria of PD patients [4].
Experimentally, inhibitors of complex I of the mitochondrial
respiratory chain can produce the selective neuronal loss and
consequent behavioral deficits mimicking PD hallmarks. For
instance, in rodents, human and non-human primates, the
neurotoxin 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) mediates
selective damage to dopaminergic neurons of the nigro-striatal
pathway [5]. Neuronal cell death is caused by MPP
+, the active
metabolite of MPTP, which induces oxidative stress and the
opening of the mitochondrial permeability transition pore (mPTP),
the release of cytochrome c and the activation of caspases [6–8].
The mPTP results in increased permeability of the inner
mitochondrial membrane to protons, ions and other solutes
resulting in a decrease of the mitochondrial membrane potential
(Dym).
Glycogen Synthase Kinase (GSK)-3 is a proline-directed serine/
threonine kinase originally identified as a regulator of glycogen
synthase [9]. Gradually, GSK-3 appeared to be a multifaceted
enzyme, affecting a wide range of biological functions including
gene expression, cellular architecture and apoptosis [10]. Of the
two closely related isoforms, GSK-3a and GSK-3b, GSK-3b is
known to play critical roles in oxidative stress-induced neuronal
apoptosis and pathogenesis of neurodegenerative diseases [11–17].
GSK-3b is activated by phosphorylation of the tyrosine 216
residue (Tyr216) located in the kinase domain and inactivated by
phosphorylation of the amino-terminal serine 9 residue (Ser9) [18].
Recently, it has been shown that GSK-3b inhibition protects
dopaminergic neurons from MPTP toxicity, suggesting that GSK-
3b may play a key role in PD pathogenesis [19,20]. Moreover, a
chronic treatment with low lithium doses, a GSK-3b inhibitor,
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striatal dopaminergic neurodegeneration and dopamine depletion
[21]. Finally, two other PD mimetics, 6-hydroxydopamine (6-
OHDA) and rotenone, induce neuronal death through the
activation of GSK-3b [22,23,24].
The presence of GSK-3b within mitochondria has been
reported [25–28]. Many reports indicate that the inhibition of
GSK-3b reduces ischemia/reperfusion cardiac injury through the
regulation of the mPTP opening, indicating that it could exert its
functions by modulating mitochondrial activity [29–32].
The present study was designed to investigate the putative role
of GSK-3b in MPTP/MPP
+-induced mitochondrial dysfunction
and dopaminergic neuronal death, in vivo, as well as in primary
cultures of neuronal cells and immortalized neurons. Overall,
MPTP/MPP
+ induced the activation of GSK-3b by the
phosphorylation of Tyr216 in mouse brain and in both neuronal
cell models. However, on subcellular fractions of neurons, we
established that MPP
+ treatment induced specific activation of the
cytosolic pool whereas it decreased the mitochondrial pool of
active GSK-3b. This leads to the depolarization of the
mitochondrial membrane, to the activation of caspase-9 and -3
and finally to neuronal cell death. Blockade of GSK-3b activity by
selective inhibitors i.e. lithium or kenpaullone or siRNA-mediated
GSK-3b knock-down efficiently abolished these effects. These
findings suggest that GSK-3b activity is critical for neuronal death
in response to the mitochondrial stressor MPTP/MPP
+.
Materials and Methods
Ethics statements
Experimental procedures on mice and the care given to animals
have been approved by the French Regional Committee for
Animal Use and Care # NCA/2004/06-02.
Animals
Seven weeks-old male C57BL/6 mice were purchased from
Charles River Laboratories (L’arbresle, France). All mice were held
in a temperature-controlled room maintained under a 12-h light/
dark cycle and had access to food and water available ad libitum.
In vivo MPTP treatment
Adult mice (n=5/group) received one intraperitoneal (i.p.)
injection of MPTP per day (30 mg of free base/kg of body weight
per injection; Sigma-Aldrich, St Quentin Fallavier, France) for five
consecutivedayswhereascontrolmice (n=5/group)weretreatedin
the same conditions with vehicle only (0.9% NaCl). Mice were
sacrificed 1, 3, 5, and 7 days after the last injection. After
decapitation, collected brains were quickly frozen in 2-methyl
butane at 230uC and kept at 220uC until use. MPTPhandlingand
safety measures were in accordance with published guidelines [33].
Immunohistochemistry
Brain coronal sections (12 mm thickness) were performed on a
cryostat (Leica, Nussloch, Germany). For double-staining exper-
iments, rabbit anti-TH (anti-Tyrosine Hydroxylase, Cell Signal-
ing, St Quentin-en-Yvelines, France) was used together with
mouse anti-phospho-Tyr216-GSK-3b (BD Biosciences, Le Pont
de Claix, France) as primary antibodies. Brain sections were
permeabilized and blocked in PBS, pH 7.4, containing 0.2%
CHAPS and 2% BSA (Sigma-Aldrich), then incubated with
primary antibodies diluted in PBS, pH 7.4, containing 0.1%
CHAPS and 2% BSA, for 3 h at room temperature. At the end of
the incubation time, brain sections were washed three times with
PBS and incubated with either Alexa488-conjugated or Texas-
Red-conjugated secondary antibodies (Molecular Probes, Invitro-
gen, Cergy Pontoise, France) and diamidino-49,6-phenylindol-2
dichlorhydrate (DAPI) for 1 h at room temperature. Sections were
then washed three times with PBS and prepared for microscopy
observation.
Cell cultures
Murine TSM1 neuronal cells were grown in Opti-MEM
(Invitrogen) supplemented with 10% inactivated fetal bovine
serum (FBSi, BioWest, Nuaille, France), 100 U/mL penicillin,
100 mg/mL streptomycin, and 0.1 g/L G418 (Invitrogen).
Primary cultures of mouse neurons from embryonic day 13–14
C57BL/6 mice was carried out as described previously [34].
Briefly, neurons were cultured in Neurobasal medium containing
B27 supplement (Invitrogen) and penicillin-streptomycin and used
after 6–7 days of differentiation. Cell cultures were grown at 37uC
in a humidified atmosphere of 5% C02 and 95% air.
MPP
+ (Sigma-Aldrich) was extemporaneously prepared by
solubilization into appropriate cell culture medium. TSM1 and
primary neuronal cell cultures were treated with the indicated
concentrations of MPP
+ for various times. Alternatively, neurons
were pre-incubated for 15 min with indicated concentrations of
LiCl or kenpaullone (kenp, Sigma-Aldrich) and then co-treated
with 400 mM MPP
+.
siRNA cell transfection
GSK-3b-specific small interfering RNA (siRNA) or scrambled
siRNA (Dharmacon, Perbio Science, Brebieres, France) were
transfected into TSM1 cells using Oligofectamine (Invitrogen)
according to the manufacturer’s recommendations. Cells were
used 48 h after transfection.
Immunocytochemistry
TSM1 and primary cultures of neurons were grown on
polylysine-coated glass coverslips. After treatment, cells were fixed
with 4% paraformaldehyde then permeabilized in PBS pH 7.4,
containing 0.2% CHAPS and 2% BSA. Cells were then incubated
for 3 h at room temperature with the appropriate primary
antibody (dilution 1/200) in PBS, 0.1% CHAPS and 2% BSA.
At the end of the incubation time, cells were washed three times
with PBS and incubated with either Alexa488-conjugated or
Texas-Red-conjugated secondary antibodies and DAPI for 1 h at
room temperature. For mitochondria labeling, neurons were
incubated with 100 nM MitoTracker Red CMXRos
TM dye
(Invitrogen) in the culture medium for 45 min at 37uC, then
fixed, permeabilized and labeled for phospho-Tyr216-GSK-3b as
mentioned above. Finally, cells were washed three times with PBS
and prepared for microscopy observation.
Tetramethylrhodamine methyl ester (TMRM) labeling
Coverslips with cells were mounted in a non perfusion holder
(37uC) placed on the stage of a laser-scanning confocal microscope
(TCS SP5, Leica Microsystems, Rueil-Malmaison, France)
equipped with a 636/1,4 oil immersion objective. One minute
after the beginning of each experiment, cells were loaded with the
potentiometric dye TMRM (Sigma-Aldrich) in Krebs-Ringer at a
final concentration of 30 nM at 37uC. TMRM was excited at
561 nm and its fluorescence was detected through a 570–600 nm
spectral window. In order to follow the dye equilibration between
cytosolic and mitochondrial compartments, images were collected
every 10 sec for 10 min. At the end of the equilibration period,
neuronal cultures were treated with 5 mM carbonyl cyanide p-
(trifluoromethoxy)phenylhydrazone (FCCP) (Sigma-Aldrich) as a
GSK-3b and Mitochondria
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image stacks were processed using ‘‘National Institutes of Health’’
IMAGE software
TM. The fluorescence intensity kinetic plots were
obtained by selecting 8 regions of interests (roi) and expressed as
the mean6S.D. of the mean gray values derived from all the roi
selected in each image.
Western blotting
Cells were rinsed with PBS and homogenized in lysis buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA
containing 0.5% Triton X-100 and 0.5% sodium deoxycholate).
Equal amounts of total proteins (40 mg) determined by the
Bradford method (BioRad, Marnes-La-Coquette, France) were
separated onto 12% SDS-PAGE then transferred on nitrocellulose
membrane (Schleicher & Schuell, Dassel, Germany). Blots were
incubated in PBS 0.1% Tween, 1% milk with antibodies directed
against GSK-3b (Santa Cruz Biotechnologies, Tebu-Bio, Le
Perray-en-Yvelines, France), phospho-Tyr216-GSK-3b (BD Bio-
sciences), phospho-Ser9-GSK-3b (Cell Signaling), cytochrome c
(BD Biosciences), and then with the appropriate HRP-secondary
antibody. Blots were developed using an enhanced chemolumi-
nescence system (ECL, Amersham, GE Healthcare, Orsay,
France) with a LAS3000 detector (Fuji). To correct for any
loading artifact, same blots were re-probed with either anti-b-
tubulin or anti-actin antibody (Abcam, Paris, France). Densitom-
etry analyses were performed with a ‘‘National Institutes of Health’’
IMAGE software
TM on the immuno-positive bands. Results were
expressed as a percentage of control load.
Cell fractionation
Cells were lysed in buffer containing 20 mM Hepes, pH 7.5,
250 mM sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA,
1 mM dithiothreitol and a protease inhibitor mix (Roche, Basel,
Switzerland). Homogenates were centrifuged at 7506g for 10 min
at 4uC, then supernatants were collected and centrifuged at
10 0006g for 15 min at 4uC. Resulting pellets were mitochondri-
al-enriched fractions and were washed twice in order to minimize
putative contamination with cytosolic proteins. Supernatants were
further centrifuged at 100 0006g for 1 h at 4uC, the resulting
pellets were microsomal-enriched fractions while supernatants
contained cytosolic proteins.
Cell survival measurement
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay (Promega,
Charbonnie `res-les-Bains, France), a marker of mitochondrial
activity, was done according to the manufacturer’s recommenda-
tions. The percentage of cell survival was calculated by dividing
the absorbance value of the MPP
+-treated samples by that of the
untreated control within each group.
Flow cytometry analyses
MPP
+- and untreated TSM1 neurons were pelleted and washed
twice with PBS and the percentage of cells with active caspase-3
was assessed using PE-conjugated monoclonal active caspase-3
antibody kit (Pharmingen, BD Biosciences).
To measure the mitochondrial membrane potential, TSM1 cells
were stained with fluorescent probe JC-1 (5,59,6 ,6 9-tetrachloro-
1,19,3,39-tetraethylbenzimidazole carbocyanide iodide, BD Biosci-
ences) at 1.0 mg/mL for 15 min at 37uC, washed and analyzed by
flow cytometry. Photomultiplier settings were adjusted to detect
green flurorescence of JC-1 monomers on FL-1 detector and the
red fluorescence of JC-1 aggregates on the FL2 detector. Flow
cytometry analysis was performed on a FACSCalibur
TM and the
CELLQuest
TM software. Cells were gated according to size and
scatter to eliminate dead cells and debris from analysis.
Statistic analysis
Data were expressed as the mean6SD. Statistical analyses were
performed using one-way analysis of variance (ANOVA) or
Student t-test as indicated in the figure legends. p value,0.05
was considered as statistically significant.
Results
MPTP activated GSK-3b in dopaminergic neurons of
mouse brain and in two neuronal cell models
In vivo, MPTP treatment is a well characterized and suitable
animal model of PD pathogenesis. MPTP is known to induce
selective death of dopaminergic neurons (i.e. Tyrosine Hydroxylase,
TH-positive neurons) in the substantia nigra pars compacta (SNc) and to
reproduce neuropathological features of PD in mice [35,36].
In an attempt to study the role of endogenous GSK-3b in vivo in
MPTP-induced dopaminergic neuronal cell death, we first
examined the activation of GSK-3b (i.e phosphorylation at
Tyr216 residue) in the SNc of MPTP-treated mice. Interestingly,
immunohistochemistry analysis showed a selective activation of
GSK-3b in TH-positive neurons evidenced by enhanced phos-
phorylation at Tyr 216 in remaining TH-positive neurons 7 days
post MPTP-treatment as compared to saline-injected control
brains (Figure 1A). To further confirm that the MPTP treatment
induced GSK-3b activation, the phosphorylation state of Tyr216
residue of GSK-3b was also evaluated by Western blotting in
mouse brain homogenates. The level of phospho-Tyr216-GSK-3b
was significantly increased 7 days but not one day after the MPTP
administration when compared to saline-treated controls
(Figure 1B). In preliminary experiments, we established the kinetic
of loss of TH-immunoreactive neurons in vivo. Mice were i.p.
injected with 30 mg/kg every day for 5 consecutive days, then
sacrificed 1, 3, 5 and 7 days after the last MPTP injection and
brain sections were examined for TH immunoreactivity. Neuro-
pathological examination of MPTP-treated mice revealed a
progressive decrease in the number of TH-positive neurons in
the SNc as early as 3 days after the MPTP treatment as compared
to the saline-treated mouse brains. The maximal effect was
observed 7 days after the last MPTP injection (data not shown).
MPP
+ has been extensively used as an in vitro model of PD [37].
Based on preliminary results, we systematically used, in the
following experiments with neuronal cells, a concentration of
MPP
+ leading to a significant cellular toxicity (i.e. 400 mM).
Immortalized murine cortical neurons (TSM1) or primary cultures
of neuronal cells were incubated in the presence of MPP
+ iodide
then Western blot analyses were performed on neuron homoge-
nates in order to examine the effect of MPP
+ on the
phosphorylation of GSK-3b at Tyr216 (i.e. activated GSK-3b)
and Ser9 residues (i.e. inactivated GSK-3b) (Figure 1C). MPP
+
rapidly increased the phosphorylation of GSK-3b at residue
Tyr216 in both neuronal cell types reaching a maximal effect after
1 and 2 h of incubation time for TSM1 and primary cultured
neurons respectively as compared to the saline-treated cells
(Figure 1C and 1D). Quantification after standardization of the
same blots using the anti-b-tubulin and anti-total GSK-3b
antibodies indicated a maximal effect after 1 and 2 h of MPP
+
treatment in TSM1 cells and neurons in primary cultures
respectively (126.562.3% and 180.164.5% compared to the
control conditions taken as 100%) (Figure 1D). Surprisingly, the
MPP
+-induced GSK-3b phosphorylation at Tyr216 was persistent
GSK-3b and Mitochondria
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TSM1. The level of GSK-3b phosphorylation at residue Ser9 was
less affected by MPP
+ treatment than that of Tyr216. However, a
slight increase of Ser9 phosphorylation was observed after 2 h of
MPP
+ treatment in primary cultures of neuronal cells (Figure 1C).
Pharmacological and siRNA-mediated down-regulation
of GSK-3b activity reduced MPP
+-induced neuronal cell
death
TSM1 and primary cultures of neuronal cells were incubated in
the presence of increasing concentrations of MPP
+ iodide (from
0.1 to 2 mM) for 15 h and the cell viability was evaluated using the
colorimetric MTS assay (Figure 2A). In both TSM1 and primary
neurons, MPP
+ induced neuronal cell death in a concentration
dependent manner. In both cell types, 400 mM MPP+ induced
,50% of cell death (Figure 2A).
Lithium chloride (LiCl), a selective inhibitor of GSK-3b [38],
was used to determine the implication of GSK-3b in MPP
+-
induced neuronal cell death. TSM1 and primary cultured neurons
were incubated for 15 h with 400 mM MPP
+ in the presence of
GSK-3b inhibitors i.e. kenpaullone [39] and LiCl. Microscopy
observations showed that the MPP
+ treatment induced a
significant decrease in the number of TSM1 cells and primary
neurons as compared to the control condition (Figure 2B).
Moreover, neurons exposed to MPP
+ were dramatically damaged
as reflected by the disappearance of normal cell bodies and the
presence of shortened neuritis compared to untreated control cells
Figure 1. In vivo and in cellulo GSK-3b activation by MPTP/MPP
+. (A) Seven days after the last saline or MPTP administration, coronal midbrain
slices from saline- or MPTP-treated mice were labeled with anti-TH antibody (green) and anti-phospho-Tyr216-GSK-3b (red) as described in Materials
and Methods. Merged micrographs illustrated the co-labeling (yellow) of anti-phospho-Tyr216-GSK-3b and anti-TH antibodies. Images are
representative of three independent experiments. (B) Saline and MPTP-treated mice were killed one or seven days after the end of the MPTP
administration. The brains were homogenized and equal protein amounts were analyzed by Western blotting for phospho-Tyr216-GSK-3b, total GSK-
3b and b-tubulin contents. Arrowhead indicates the phospho-Tyr216-GSK-3b, the upper immuno-positive band is a non specific labeling. (C) TSM1
(left) and primary cultures of neurons (right) were incubated with saline (ctrl) or MPP
+ (400 mM) for the indicated times (0.5, 1, 2 and 4 h). Total
proteins (40 mg) were analyzed for phospho-Tyr216-GSK-3b, phospho-Ser9-GSK-3b, total GSK-3b and b-tubulin by Western blotting. (D)
Quantification of blots from three independents experiments performed on TSM1 (left) and primary cultured neurons (right). The phospho-
Tyr216-GSK-3b content in every condition was normalized to the total GSK-3b content and expressed as percentage of the control condition. The
results are mean6SD and statistical analysis was done using Student t-test. *p,0.01 versus untreated sample.
doi:10.1371/journal.pone.0005491.g001
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+-induced neuronal cell death. (A) TSM1 and primary cultured neurons
were treated with MPP
+ (from 0.1 to 2 mM) for 15 h and cell viability was monitored by MTS assay. The data are expressed as the percentage of viable
neurons when compared to untreated neurons and are the mean of three independent experiments with triplicate determinations 6S.D. (B) Phase-
contrast pictures of representative microscopic fields of TSM1 (left) and primary cultured neurons (right) pre-treated with 25 mM LiCl or 25 mM
kenpaullone for 15 min, and then treated with saline or MPP
+ for additional 15 h at 37uC. Magnification, 610. (C) TSM1 neurons (left) and mouse
primary neurons (right) were pre-treated with LiCl or kenpaullone (25 mM and 25 mM, respectively), then incubated with MPP
+ (400 mM) for 15 h at
37uC and cell viability was assessed using the MTS assay. The data are expressed as the percentage of viable neurons when compared to untreated
neurons and are the mean of nine independent experiments with triplicate samples 6S.D. One-way ANOVA *p,0.01 versus saline-treated cells. (D)
TSM1 neurons were pre-treated with LiCl (25 mM) for 15 min and co-incubated with 400 mM MPP
+ for the indicated times (0.5, 1, 2 and 4 h) and total
proteins were extracted and anaylzed for phospho-Tyr216-GSK-3b, total GSK-3b and b-tubulin contents by Western blotting. (E, F) TSM1 cells were
transfected with scrambled siRNA (200 nM) or GSK-3b specific siRNA (100 or 200 nM) as described in Materials and Methods. Two days post-
transfection, cells lysates were analyzed for total GSK-3b immunoreactivity (upper panel) by Western blotting (F). To determine the correction factor of
load, blots were reprobed with the anti-b-tubulin antibody (middle panel). The expression level of GSK-3b was estimated by densitometry analyses
performed with a ‘‘National Institutes of Health’’ IMAGE software and expressed as the percent of control conditions. (E) Alternatively, scrambled- or
GSK-3b specific- siRNA-transfected cells were treated with 400 mM MPP
+ for 15 h at 37uC and the cell viability was monitored using MTS assay.
GSK-3b and Mitochondria
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lone or LiCl prevented MPP
+-induced neurotoxicity (Figure 2B).
Neuronal viability was monitored by measuring the reduction of
mitochondrial activity using the MTS assay. Preliminary exper-
iments allowed us to show that the optimal protective effect of LiCl
and kenpaullone on MPP
+-induced cell death was obtained at
25 mM and 25 mM, respectively (data not shown). In TSM1 and
primary cultures of neuronal cells, LiCl or kenpaullone signifi-
cantly reduced the MPP
+-induced toxicity (Figure 2C). Treatment
of TSM1 cells and primary neurons with 400 mM MPP
+
decreased by ,60% and ,80% the cell viability as compared to
the control, respectively. Co-treatment with 25 mM LiCl or
25 mM kenpaullone significantly protected TSM1 from the MPP
+-
induced death (Figure 2C). No significant toxicity was found when
neurons were incubated with 25 mM LiCl or 25 mM kenpaullone
alone (Figure 2B and 2C).
In an attempt to check the effect of LiCl on MPP
+-induced
GSK-3b activation, TSM1 cells were pre-treated with 25 mM
LiCl for 15 min and then co-incubated with 400 mM MPP
+ for
various incubation times. Western blot analyses using anti-
phospho-Tyr216-GSK-3b specific antibodies showed that LiCl
prevented the MPP
+-induced phosphorylation of GSK-3b at
Tyr216 residue suggesting that LiCl hampered the MPP
+-induced
activation of GSK-3b (Figure 2D).
We used RNA interference, a gene silencing method, to further
study the role of GSK-3b in MPP
+-induced neuronal cell death.
GSK-3b specific or control siRNA were transfected into TSM1
neurons and the level of GSK-3b was estimated by Western blot
analysis. 200 nM of specific GSK-3b siRNA induced a ,70%
decrease of the expression level of GSK-3b (Figure 2E). siRNA
transfected cells were then treated with MPP
+ for an additional
15 h and the cell viability was monitored. The survival of GSK-3b
siRNA-transfected cells was about 40% higher than that of the
scrambled siRNA-transfected cells following MPP
+ treatment
indicating that MPP
+-induced neurotoxicity was at least partially
dependent on the expression of GSK-3b (Figure 2F).
GSK-3b inhibitors prevented MPP
+-induced caspase-9
and caspase-3 activation
To further characterize the intracellular pathways involved in
the cell death induced by MPP
+, we examined by fluorimetric
assays and Western blot the activation of caspase-9 and caspase-3
after incubation with MPP
+ in the presence or in the absence of
pre-treatment with LiCl and kenpaullone (Figure 3). The MPP
+
treatment induced a significant activation of caspase-9 in both
neuronal models as compared to the untreated control, the
maximal significant effect being observed after a 2 h-treatment for
TSM1 cells and a 1 h-treatment for primary neurons
(129.37611.61% and 165.80610.92% compared to the control
conditions taken as 100%, Figure 3A and 3D). Significant caspase-
3 activation was also observed in both cell types after as soon as
1 h after MPP+ treatment, reaching 138.8465.44% of the control
in TSM1 cells and 182.2666.10% of the control in primary
neurons (Figure 3B and 3E). Western blot analysis confirmed the
increase of active caspase-3 immunoreactivity and the concomi-
tant decrease of total caspase-9 level in TSM1 (Figure 3C) and
primary cultured neurons (Figure 3D and 3E) upon MPP
+
treatment. As shown by fluorimetric and Western blot analysis,
pre-incubation with 25 mM LiCl prevented the MPP
+-induced
caspase-9 and -3 activation (Figure 3A–3E). Similar results were
found by flow cytometry analysis of activated caspase-3 after
incubation with MPP
+ in the presence or in the absence of pre-
treatment with LiCl and kenpaullone (data not shown). The MPP
+
treatment induced the activation of caspase-3 in TSM1 neurons
up to 233.9% as compared to the untreated control of active
caspase-3 content of TSM1 cells. Pre-incubation with LiCl or
kenpaullone minimized the MPP
+-induced caspase-3 activation
(194.9% and 198.3%, respectively).
MPP
+ differentially affected GSK-3b phosphorylation at
residue Tyr216 in mitochondrial and cytosolic fractions
Previous studies have shown that GSK-3b exerts its functions via
the mitochondrial activity, by modulating transport through the
outer membrane of the mitochondria, regulating the opening of
the mPTP or mediating the access of Bax to the mitochondria
[27,31,40]. Using immunocytochemistry we first checked that in
our neuronal models GSK-3b was indeed detectable within
mitochondria. To do so, TSM1 and primary cultured neurons
were loaded with the MitoTracker
TM dye, then stained with
phospho-Tyr216-GSK-3b specific antibody. Microscopy observa-
tion revealed that in both neuronal models, phospho-Tyr216-
GSK-3b partially localized within mitochondria as evidenced by
the overlap between phospho-Tyr216-GSK-3b and MitoTrack-
er
TM labeling (Figure 4A). We then investigated the effect on
MPP
+ treatment on the subcellular distribution of active and
inactive forms of GSK-3b in TSM1 and primary neurons. MPP
+-
treated or untreated cells were submitted to differential subcellular
fractionation and extracted proteins from the cytosolic and
mitochondrial compartments were analyzed by Western blot. As
early as 1 h after the MPP
+ treatment, there was a marked
decrease in phospho-Tyr216-GSK-3b in the mitochondrial
fractions of both cell types that was even more pronounced after
2 h of MPP
+ incubation time (Figure 4B and 4C). On the opposite,
the cytosolic fraction of phospho-Tyr216-GSK-3b was significant-
ly increased after the MPP
+ treatment (Figure 4B and 4C). The
mitochondrial and cytoplasmic fractions of the inactive form of the
kinase i.e. phospho-Ser9-GSK-3b were not affected by MPP
+
treatment in both compartments (Figure 4B). No significant effect
was shown on the subcellular distribution of total GSK-3b,
suggesting that modifications of the level of active form of GSK-3b
likely resulted from specific phosphorylation mechanisms and not
from protein relocation or neosynthesize process. To monitor the
purity of mitochondrial and cytosolic fractions, COXIV and
GAPDH immunoreactivities were assessed as mitochondrial and
cytosolic specific markers, respectively (Figure 4B). Interestingly,
the modifications of phospho-Tyr216-GSK-3b in cytosolic and
mitochondrial fractions upon MPP
+ treatment were significantly
reduced by LiCl pre-treatment in both cell types (Figure 4C).
Pharmacological and siRNA-mediated down-regulation
of GSK-3b activity attenuated MPP
+-induced decrease of
mitochondrial membrane potential
One common feature of PD is the reduction of complex I
activity in the SNc, supporting the hypothesis that nigral
dopaminergic neurons are highly vulnerable to stress arising from
mitochondrial dysfunction [41]. To investigate the involvement of
mitochondria in MPP
+-induced neuronal cell death through GSK-
Survival rate in every group was normalized to the untreated control cells. Error bars represent the S.D. for three independent experiments.
Statistically significant differences were obtained between siRNA specific GSK-3b- and scrambled siRNA-transfected cells treated with 400 mM MPP+
using Student t-test (*p,0.05).
doi:10.1371/journal.pone.0005491.g002
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membrane potential after MPP
+ treatment by flow cytometry
analysis using the fluorescent probe JC-1. JC-1 is selectively taken
up by the mitochondria and is a reliable indicator of change of the
mitochondrial membrane potential (DYm). We first studied the
effects of a dose-response of MPP
+ (from 100 to 600 mM) on
mitochondrial membrane potential in TSM1 neurons (Figure 5A).
Increasing concentrations of MPP
+ induced a dose-dependent
reduction of the fluorescence intensity as compared to that
obtained with untreated cells, indicating a progressive MPP
+-
dependent depolarization of the mitochondrial membrane
(Figure 5A). To investigate whether GSK-3b exerts its neurotoxic
role by modifying the mitochondria membrane potential,
scrambled or GSK-3b specific siRNA-transfected TSM1 cells
were treated with MPP
+ alone or in combination with LiCl or
kenpaullone. The number of cells with depolarized mitochondrial
membrane potential remained unchanged in GSK-3b specific
siRNA-transfected cells whereas it was increased by a two-fold
factor in scrambled siRNA-transfected cells upon MPP
+ treatment
(Figure 5B). As expected, pre-treatment with LiCl or kenpaullone
totally abolished the effect of MPP
+ on the mitochondrial
membrane potential in scrambled siRNA-transfected cells. These
results indicate that the expression of GSK3b is required for the
MPP
+-induced alterations of the mitochondrial membrane
potential.
The fluorescent membrane-permeant cationic probe tetra-
methylrhodamine methyl ester (TMRM) has become one of the
most frequently used probes in the analysis of variations of the
Figure 3. GSK-3b inhibitors prevented MPP
+-induced caspases-9 and -3 activation. (A, B, C) TSM1 neurons were pre-treated with saline or
25 mM LiCl and then incubated with 400 mM MPP
+ for indicated times (1, 2, 4, or 6 h). Intracellular caspase-9 (A) and caspase-3 (B) activities were
measured by fluorescence enzymatic assay in cell homogenates. The data are expressed as the percentage of control when compared to untreated
neurons and are the mean of three independent experiments with triplicate samples 6S.D. Statistical analysis was done using Student t-test
(***p,0.005 versus untreated sample). (C) TSM1 cells were pre-treated or not with 25 mM LiCl and incubated with saline (ctrl) or MPP
+ (400 mM) for 1
or 2 h. Total proteins (40 mg) were analyzed for active caspase-3, total caspase-9 and actin contents by Western blotting. (D, E) Primary cultured
neurons were pre-treated with saline or 25 mM LiCl and then incubated with 400 mM MPP
+ for indicated times (1, 2, 4, or 6 h). Intracellular caspase-9
(D) and caspase-3 (E) activities were measured by fluorescence enzymatic assay in cell homogenates. The data are expressed as the percentage of
control when compared to untreated neurons and are the mean of three independent experiments with triplicate samples 6S.D. Statistical analysis
was done using Student t-test (*p,0.05 versus untreated sample). Total caspase-9 (D) and active caspase-3 (E) contents were analyzed by Western
blotting of primary neurons pre-treated or not with 25 mM LiCl and incubated with saline (ctrl) or MPP
+ (400 mM) for 1 or 2 h.
doi:10.1371/journal.pone.0005491.g003
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PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5491Figure 4. GSK-3b partially localized within mitochondria and MPP
+ differentially affected phospho-Tyr216-GSK-3b in mitochondrial
and cytosolic fractions. (A) Fluorescence microscopy pictures of TSM1 and primary cultures of neurons loaded with 100 nM MitoTracker
TM (red),
then fixed, permeabilized and stained for phospho-Tyr216-GSK-3b (green) and nuclei (DAPI, blue). Magnification 625. (B, C) TSM1 neurons (left) and
cultured primary neurons (right) were treated with 400 mM MPP
+ for 1 and 2 h then submitted to subcellular fractionation in order to separate
mitochondrial and cytosolic fractions, as described in Materials and Methods. Both fractions were analyzed for phospho-Tyr216-GSK-3b, phospho-
Ser9-GSK-3b, total GSK-3b, COXIV and GAPDH contents by Western blotting (B). (C) Densitometry analyses of four to eight independent experiments
were carried out to quantify the phospho-Tyr216-GSK-3b content in mitochondrial and cytosolic cellular fractions of vehicle- and LiCl-pretreated
TSM1 (left) and primary cultured neurons (right). Data are expressed as percentage of the untreated samples. Statistical analysis was done using
Student t-test (* p,0.05, ** p,0.01, ***p,0.005 versus untreated sample).
doi:10.1371/journal.pone.0005491.g004
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5491Figure 5. GSK-3b contributed to MPP
+-induced TSM1 neuronal cell death through alterations of the mitochondrial membrane
potential. (A) TSM1 neurons were treated with the indicated concentrations of MPP
+ for 8 h then cells were stained with JC-1 and analyzed by flow
cytometry. (B) TSM1 cells were cultured for 24 h then transfected with scrambled or GSK-3b-specific siRNA (200 nM). Two days post-transfection, cells
were pre-treated with saline buffer or 25 mM LiCl or 25 mM kenpaullone (kenp), then co-incubated or not with MPP
+ (400 mM) for 8 h. Cells were
stained with JC-1 as described in Materials and Methods and prepared for flow cytometry analysis. The results are expressed as the percent of cells
with depolarized mitochondrial membrane potential (Ym). (C, D) intact primary neurons were pre-treated of not with 25 mM LiCl, then co-incubated
or not with MPP+ (400 mM) for 4 h. Cells were placed on the stage on a laser-scanning confocal microscope and images were collected every
10 seconds for 10 minutes. One minute after the beginning of experiment, neurons were loaded with 30 nM TMRM (arrow) and one minute before
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exhibits very low toxicity and displays rapid and reversible
membrane equilibration properties. We performed confocal
microscopy analysis on intact primary cultured neurons in order
to compare the kinetic and level of TMRM integration in
mitochondria of control, MPP
+ and LiCl/MPP
+-treated neuronal
cells. In control neurons, TMRM rapidly entered within
mitochondria where it accumulated in an inner-membrane
potential dependent manner (Figure 5C), as illustrated by the
rapid increase of mean fluorescence intensity of untreated cells
(Figure 5D). In MPP
+-treated cells, TMRM only minimally
entered within mitochondria and almost no TMRM fluorescence
was detected (Figure 5C and 5D), indicating that MPP
+ induced
the depolarization of mitochondrial membrane potential. Inter-
estingly, TMRM accumulated similarly in control cells and in
LiCl/MPP
+ co-treated neurons, suggesting that LiCl treatment
prevented the MPP
+-induced mitochondrial membrane depolar-
ization (Figure 5C and 5D). LiCl treatment alone didn’t affect
mitochondria morphology and distribution (Figure 5C) and
strongly increased TMRM mean fluorescence intensity during
the course of the experiment, indicating that LiCl changed
mitochondrial membrane potential (Figure 5D). FCCP, a
mitochondrial uncoupler, was used as control because it induced
a mitochondrial membrane potential collapse in intact cells. When
FCCP was added to neurons, TMRM no longer accumulated
inside mitochondria and became evenly distributed throughout the
cytosol, as shown by the loss of TMRM fluorescence in control
cells (Figure 5D).Taken together,these results indicated that GSK-
3b triggered a strong depolarization of the mitochondrial
membrane potential in neuronal cells exposed to MPP
+.
Discussion
In the present study, we examined the implication of GSK-3b in
MPP
+-induced mitochondrial dysfunction, and the putative
protective role of GSK-3b inhibition on MPP
+-mediated neuro-
toxicity.
The role of mitochondria in the pathogenesis of several
neurodegenerative disorders, including PD, has been well
documented. Consistent deficits in the subunits and activity of
mitochondrial complex I of the electron transport chain in blood
platelets and substantia nigra of PD patients are prominent
phenomena [42,43]. Reduced complex I activity is also seen in
cytoplasmic hybrid cell lines containing DNA from PD patients
[44]. The role of mitochondrial dysfunction in PD also extends
beyond that of a respiratory chain defect since mutations in three
nuclear genes (PINK1, DJ1 and Omi) encoding mitochondrial
proteins have been described in familial forms of PD. However,
little is known regarding the molecular mechanisms leading to
mitochondrial dysfunction but reduced mitochondrial membrane
potential might be considered as an initial and irreversible step
towards apoptosis.
GSK-3b is a well-known determinant in apoptotic process
leading to neuronal cell death in several paradigms. For instance,
the involvement of GSK-3b in neuronal apoptosis has been
demonstrated following excitotoxic treatment [45], staurosporine-
induced cell death [46], b-amyloid and MPTP treatments [47,48].
Activated GSK-3b, which inhibits heat shock transcription factor
(HSTF)-1 and activates the mitochondrial death pathway, results
in increased cytochrome c release from mitochondria. This, in
turn, activates successively caspase-9 and caspase-3, accompanied
by poly (ADP-ribose) polymerase (PARP) cleavage [46,49,50,51].
Moreover, GSK-3b has been shown to be located into several cell
compartments such as cytosol, nucleus and mitochondria by both
microscopy and immunoblotting experiments [26,52,27,28]. The
translocation of GSK-3b from the cytosol to the nucleus is known
to be one of the regulatory mechanisms of its function [14,53].
However, the significance of the presence of GSK-3b in
mitochondria is still completely misunderstood. GSK-3b may
play crucial roles in the regulation of cell death and survival by
modulating mitochondrial apoptotic cell death pathway [54,55].
Interestingly, GSK-3b has also been described to be involved in
the regulation of opening of the mPTP, an event that can occur
under conditions of oxidative stress or electron transport chain
inhibition, leading to collapse of the mitochondrial membrane
potential [30,56,57].
The current study demonstrates several findings regarding the
role of GSK-3b in MPP
+-induced mitochondrial dysfunction and
neuronal cell death. The best-characterized mechanism for the
inactivation of GSK-3b occurs through the phosphorylation of its
N-terminus at Ser9 by the kinase Akt [58]. However, in our study,
we show that, in vivo, MPTP treatment induces a progressive loss of
TH-positive neurons concomitant with an increase of phospho-
Tyr216 GSK-3b in remaining dopaminergic neurons, indicating
that the activation of GSK-3b by specific phosphorylation of
Tyr216 may be involved in the MPP
+-dependent neuronal cell
death process. These in vivo results are in agreement with
observations performed in immortalized TSM1 and primary
cultured neurons. Indeed, in both neuronal cell types, the
treatment with MPP
+ induced an increase in the phosphorylation
at Tyr216 of GSK-3b whereas only negligible decrease in the
amount of phospho-Ser9 GSK-3b was observed. Thus, MPP
+
does not appear to regulate the Akt-mediated phosphorylation of
GSK-3b on Ser9, a result that differs from previous studies using
different cell models [19,22].
We demonstrated for the first time a cellular compartment-
specifc regulation process of GSK-3b activity upon MPP
+-
treatment. Indeed, in MPP
+-treated neurons, the active form of
GSK-3b increases in the cytosol and concomitantly decreases in
the mitochondrial fraction leading to a collapse of the mitochon-
drial membrane potential. The translocation of GSK-3b from the
cytosol to mitochondria and its physical interaction with
mitochondrial permeability transition pore complex has been
previously suggested in an ischemia/reperfusion paradigm [57].
Despite the fact that the total GSK-3b amount and its distribution
do not appear to be affected by MPP
+ treatment, we cannot rule
out the possibility of a translocation of the active form of GSK-3b
from the mitochondria to the cytosol. Therefore, the active form of
GSK-3b present in mitochondria could be determinant for the
maintenance of the mitochondrial membrane potential. Consistent
with this hypothesis, LiCl-treated neurons present higher mito-
chondrial membrane potential than untreated cells (Figure 4D).
Moreover, we showed that the regulation of GSK-3b activity
triggers MPP
+-induced mitochondrial membrane depolarization,
and subsequent mitochondrial-dependent activation of the caspase
cascade. Taken together, our results suggest a dual role for active
GSK-3b according to its subcellular location. MPP
+ induces
neuronal cell death through the mitochondrial dysfunction closely
the end of recording, 5 mM FCCP was added to the incubation medium (arrow). (C) Primary neurons pictures were collected 10 minutes after TMRM
(green) and Hoechst dye (red) was added to the incubation medium. Magnification, 663. (D) The fluorescence intensity plots were obtained by
selecting eight roi and expressed as the mean6S.D. of the mean gray values derived from all the selected roi in each image.
doi:10.1371/journal.pone.0005491.g005
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and the up-regulation of active cytosolic form of the kinase.
Finally, to precisely evaluate the role of GSK-3b in PD-related
cell death, we inhibited GSK-3b activity using two selective GSK-
3b inhibitors, LiCl and kenpaullone, and gene silencing with a
siRNA targeting GSK-3b. Lithium is widely used for the treatment
of maniac depression [59], but it is also well known for its
neuroprotective properties [60,61]. Indeed, several reports have
demonstrated that lithium, in neuronal cell models and in vivo, has
neuroprotective activity via the up regulation of antiapoptotic and
reduction of proapoptotic Bcl-2 family proteins, including Bcl-2
and Bax [21,62–65]. Previous studies have demonstrated that
GSK-3b contributes to the death of a wide variety of cells
including SH-SY5Y, PC12 or cerebellar granule neurons
[22,24,48,66–68]. Moreover, the specific inhibition of GSK-3b
could protect SH-SY5Y cells [20] and dopaminergic neurons
against MPTP toxicity [19]. In this study, we show that LiCl
blocked MPP
+-induced phospho-Tyr216-GSK-3b in both TSM1
and primary cultured neurons and that LiCl and kenpaullone
protected neurons from MPP
+-induced neuronal phenotypic
damages, neurotoxicity and apoptotic cell death.
GSK-3b is likely the major target of lithium to elicit
neuroprotection, although other targets have also been described
[69,70]. However, we show that silencing the expression of GSK-
3b by specific siRNA protected neurons against MPP
+ toxicity and
no synergistic neuroprotective effect of lithium can be observed,
demonstrating that the neuroprotective effect of lithium actually
involved GSK-3b inhibition.
In summary, we clearly demonstrated the central role of GSK-
3b in MPTP/MPP
+-mediated neuronal cell death and we showed
that differential GSK-3b regulations take place within mitochon-
dria and cytosol. Further investigations will be required to
precisely determine the role of mitochondrial GSK-3b in
physiological conditions. However, its activity may contribute to
variation of the mitochondrial membrane potential. Our results
highlight differential regulation of GSK-3b activity according to its
subcellular compartimentalization. Indeed, inhibition of GSK-3b
activity with specific inhibitors or siRNA significantly protected
neurons from MPP
+-induced cell death. New therapeutic strategy
for PD targeting GSK-3b inhibition deserves to be evaluated
keeping in mind the specific regulation of the different GSK-3b
subcellular pools.
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